Search

Researchers from Massachusetts General Hospital have conducted studies on allotransplantation, specifically focusing on the intercellular transfer of MHC molecules in T cell alloimmunity and allotransplantation. After the transplantation of allogeneic tissues and organs, recipient T cells recognize donor MHC molecules, leading to an immune response and potential rejection of the graft. The researchers found that this recognition can occur through two pathways: the direct pathway, where T cells recognize intact allogeneic MHC molecules on donor cells, and the indirect pathway, where T cells recognize donor MHC peptides presented by recipient antigen-presenting cells. The article provides an overview of recent studies on the role of intercellular exchange of MHC molecules in T cell alloimmunity and its contribution to allograft rejection and tolerance. The research was supported by the NIH National Institute of Diabetes & Digestive & Kidney Diseases. [Extracted from the article]

A recent study conducted by researchers at the National Institutes of Health explores the role of Galectin-1 (Gal-1) in hematopoietic cell engraftment in murine MHC-mismatched allotransplantation. The study focuses on haploidentical hematopoietic cell transplantation (haplo-HCT) and its association with an increased risk of allograft rejection. The researchers found that Gal-1 may favor hematopoietic stem cell (HSC) engraftment in the murine model, and Gal-1-expressing regulatory T cells (Tregs) are associated with inducing immune tolerance and stable mixed chimerism after HCT. This research provides valuable insights into the mechanisms of allotransplantation and may have implications for improving transplant outcomes. [Extracted from the article]

A new study conducted by researchers at the Department of Nephrology and Dialysis has identified a novel antigen called protocadherin FAT1 in patients with membranous nephropathy (MN) who have undergone allogeneic hematopoietic stem cell transplantation (HSCT). The study presents a case series of MN patients after HSCT and highlights the importance of specific antigen testing in establishing the relationship between MN and HSCT. The researchers suggest that serum testing for anti-FAT1 antibodies could be significant in diagnosing FAT1-associated MN in HSCT patients. This research provides valuable insights into the development and diagnosis of MN after HSCT. [Extracted from the article]

A recent study conducted in Maharashtra, India, explores the restoration of hand function in individuals with bilateral wrist-level hand amputations. The researchers discuss various options for functional restoration, including Krukenberg's operation, toe transfers, hand allotransplantation, and prosthetics. The study presents a unique case in which a patient underwent a single-stage surgery to reconstruct both hands using three toes and free flaps. The procedure successfully restored grip and allowed the patient to resume daily activities and return to work. The researchers suggest that this approach could be a potential alternative to expensive prosthetics and hand allotransplantation for individuals with bilateral hand amputations. [Extracted from the article]

A recent study conducted by researchers at Johns Hopkins University in Baltimore, Maryland, explored the effects of growth hormone (GH) on nerve regeneration and alloimmunity in vascularized composite allotransplantation. The study found that GH treatment improved neuromuscular junction reinnervation and grip strength in rats undergoing forelimb transplantation. Importantly, the study also found no significant differences in rejection rates between the GH-treated group and the control group. These findings suggest that GH may be a promising therapeutic option for improving motor functional recovery in upper extremity transplantation without increasing the risk of rejection. [Extracted from the article]

A recent study conducted by researchers from Mayo Clinic explores the role of shared decision making (SDM) in vascularized composite allotransplantation (VCA), specifically in the context of hand transplants. VCA, which involves transplanting a new limb for patients who have lost the lower part of an arm, comes with significant risks and requires extensive evaluation and decision making. The traditional models of SDM, which focus on weighing the potential effects of treatments, are not well-suited to address the complex issues involved in VCA decision making. The researchers propose a model called Purposeful SDM, which extends the range of issues that SDM can address and provides support for patients in their unique situations. This study has implications for improving outcomes and practice in VCA decision making. [Extracted from the article]

Researchers at Seoul National University in South Korea have conducted a study on gene transfer in skin flap allotransplantation. They aimed to determine the potential role of microRNAs (miRNAs) as biomarkers of acute rejection and immune tolerance. The study found that viral IL-10 gene transfer improved flap survival and reduced acute rejection response in the experimental group compared to the control group. Additionally, certain miRNAs were upregulated in the experimental group, suggesting their potential as biomarkers of immune tolerance. This research provides insights into the use of gene transfer as an immunosuppressive strategy in allotransplantation. [Extracted from the article]

A recent study conducted by Duke University in Durham, North Carolina, has resulted in the first revision of the Banff 2007 working classification of skin-containing vascularized composite allograft (VCA) pathology. The study involved a consensus among 83 clinicians and researchers, followed by international surveys and discussions, to identify and define vascular changes in severe rejection and establish diagnostic criteria. The proposal represents an international consensus on the topic and provides a scoring system and reporting system for vascular changes in VCA pathology. The research has been peer-reviewed and published in the American Journal of Transplantation. [Extracted from the article]

A recent study conducted by researchers at the Medical University of Innsbruck in Austria explores the field of allotransplantation, specifically focusing on vascularized composite allotransplantation (VCA) for upper extremity transplantation (UET). The study emphasizes the importance of interdisciplinary collaboration and strong leadership in establishing a successful UET program. The researchers conducted interviews with healthcare professionals and patients to identify factors that contribute to a successful outcome, including functional status before and after surgery, preparation for transplant, shared decision-making, rehabilitation, and psychosocial support. The study concludes that effective communication, therapy planning, adherence, and follow-up are crucial for overall success in transplantation medicine. [Extracted from the article]

A new study from Zhejiang University School of Medicine in China explores tissue engineering in vascularized composite allotransplantation (VCA), a promising therapy for repairing and reconstructing the face or body after trauma. The study highlights the challenges associated with VCA, such as tissue rejection and limited protocols for clinical application. The researchers aim to develop tissue engineering methods to prolong the survival of VCA grafts, delay rejection, and promote tissue regeneration. This review provides new ideas for future research on VCA treatment. [Extracted from the article]

A study conducted at Massachusetts General Hospital explored the use of machine perfusion (MP) as a method for preserving vascularized composite allografts (VCA) in allotransplantation. The study compared the outcomes of VCA preservation using oxygenated acellular subnormothermic machine perfusion (SNMP) for 24 hours versus static cold storage (SCS) at 4°C. The results showed that the SNMP protocol generated better clinical and histological outcomes in allotransplantation compared to SCS. This research provides new insights into the field of allotransplantation and may have implications for improving the preservation of VCA in transplant medicine. [Extracted from the article]

A recent study conducted by Yale University School of Medicine investigated the immunological processes in deeper tissues of vascularized composite allografts (VCAs), specifically in face transplant patients. The study found that patients who received donor-derived lymph nodes developed bilateral lymphadenopathy of the submental or submandibular superficial lymph nodes. Histological analysis revealed increased histiocytes and apoptosis, suggesting necrotizing histiocytic lymphadenitis, as well as the presence of donor and recipient lymphocytes. The study highlights the need for further research to understand the role of donor-derived immune cells in allograft rejection. [Extracted from the article]

A recent study from the National Autonomous University of Mexico (UNAM) explores the role of regulatory T cells (Tregs) in immune response homeostasis. The study highlights the potential of induced Tregs (iTregs) in the treatment of inflammatory disorders, autoimmune diseases, and allogeneic transplant rejection. The researchers discuss the biological characteristics of iTregs, as well as the factors involved in their regulation and stability. They also address the challenges and opportunities of using iTregs as immunotherapeutic tools in clinical trials. This research provides valuable insights into the potential of iTregs in the field of immunotherapy. [Extracted from the article]

A recent study conducted at the University of Illinois in Chicago explored the use of parathyroid allotransplantation as a treatment for hypoparathyroidism, a rare endocrine disorder characterized by inadequate parathyroid hormone secretion. The study involved three patients who underwent parathyroid allotransplantation, and the outcomes of interest were symptomatic relief, improvement in calcium levels, and time to graft failure. The results showed that all three patients experienced significant improvement in their symptoms, although two of them required multiple procedures to sustain symptom control. The researchers concluded that parathyroid allotransplantation could be beneficial for patients who do not respond to medical treatment. [Extracted from the article]

Researchers from Tufts University School of Medicine have published a case report on post-transplant lymphoproliferative disorder (PTLD) as a serious complication of vascularized composite allotransplantation (VCA). VCA is an emerging field in transplant surgery, but it carries risks for complications related to the procedure and subsequent immunosuppression. The researchers present a case of PTLD after bilateral upper extremity transplantation and review all known cases of PTLD after VCA, focusing on the unique epidemiology, presentation, and treatment in this population. This information is available in the journal article "Case Report: Post-transplant lymphoproliferative disorder as a serious complication of vascularized composite allotransplantation" published in Frontiers in Transplantation. [Extracted from the article]

A recent study conducted by researchers at the University of Louisville in Kentucky explored the rejection patterns in vascularized composite allotransplantation (VCA) using a rat osteomyocutaneous flap model. The study found that graft loss in VCA is more commonly associated with vasculopathy and chronic rejection (CR) rather than acute cellular rejection (ACR). The researchers developed a rat model that mimics these rejection patterns and demonstrated the potential of the model for investigating rejection mechanisms and treatment interventions. The study concluded that this adjustable experimental model will allow for the study of variables and interventions that may initiate or mitigate vasculopathy and CR in VCA. [Extracted from the article]

A recent study conducted by the National Heart Lung and Blood Institute in Bethesda, Maryland, explores the use of low-dose post-transplant cyclophosphamide (PT-Cy) and sirolimus in inducing mixed chimerism in allogeneic hematopoietic cell transplantation (allo-HCT). The researchers found that the combination of PT-Cy and sirolimus, along with cytotoxic T lymphocyte-associated antigen-4 immunoglobulin (CTLA4-Ig) or T-cell depleting anti-Thy1.2 (Thy), can promote immune tolerance and allograft survival. The study suggests that this approach may be considered to reduce graft rejection in patients undergoing allo-HCT. The research was supported by the NIH National Heart Lung & Blood Institute and other organizations. [Extracted from the article]

A recent report from researchers at the University Health Network in Toronto, Canada discusses the challenges and current methods of tolerance induction in vascularized composite allotransplantation (VCA). VCA involves the transplantation of multiple tissues, such as skin, muscle, bone, nerve, and vessels, as a functional unit to patients with major tissue trauma and functional deficits. While the surgical feasibility of VCA has been optimized, graft rejection remains an issue. The review provides an overview of the cell populations and mechanisms involved in VCA rejection, as well as the specific tissues affected. The researchers highlight the need for less risky methods of inducing graft tolerance, as current immunosuppressing regimens put patients at risk for malignancies, infections, and cancers. [Extracted from the article]

A study conducted by researchers at the University of Pittsburgh investigated the effects of local versus systemic delivery of adipose stem cells (ASCs) on the survival of vascularized composite allotransplants (VCAs) in a rat hind-limb model. The study found that local delivery of ASCs significantly prolonged allograft survival compared to systemic delivery. The ASC-treated recipients also showed increased donor cell chimerism and regulatory T-cells, and accepted secondary donor skin allografts without additional immunosuppression. The findings suggest that local delivery of ASCs could be a promising approach to improve the survival of limb and face allografts, potentially reducing the need for systemic immunosuppression. [Extracted from the article]

This article discusses a clinical trial, NCT06242496, that focuses on brain abscesses in transplant recipients. Brain abscesses are a serious complication for these patients, and understanding their epidemiology is crucial for diagnosis and management. The trial aims to study the clinical and microbiological characteristics of brain abscesses, compare them between different types of transplant recipients, and identify predictors and factors associated with patient survival. The trial will also assess the current management of post-transplant brain abscesses and the one-year all-cause mortality rate. The study is planned to be conducted retrospectively with 200 participants, and is estimated to be completed by February 1, 2025. [Extracted from the article]

A study conducted by researchers at Charite University Hospital and School of Medicine in Berlin, Germany, has found that moderate low molecular weight heparin (LMWH) anticoagulation improves the success rate of hind limb allotransplantation in mice. The researchers performed fifty allogeneic hind limb transplantations using different anticoagulation protocols and found that treatment with a moderate dose of LMWH reduced thromboembolic events and improved graft and animal survival. The study suggests that LMWH could be used to prevent vascular complications in hind limb transplants. [Extracted from the article]

A recent study conducted by researchers at the University of Sao Paulo (USP) aimed to identify the risk factors associated with early mortality following allogeneic stem-cell transplantation (HSCT) for acute lymphoblastic leukemia (ALL) in Brazilian centers. The study included 275 patients and found that factors such as graft source, baseline KPS, gender, Ph-positive status, refractory disease status, umbilical cord blood source, and donor age were statistically related to early mortality. The study concluded that reducing early mortality rates is crucial in resource-constrained settings to improve outcomes, and the findings could help enhance donor selection and optimize HSCT indications in Brazil. [Extracted from the article]

A recent study conducted by researchers from Yale University School of Medicine examined the cost-effectiveness of allotransplantation and gene therapy for pediatric patients with sickle cell disease (SCD) in the United States. The study found that both allotransplantation and gene therapy were equitable treatment options for SCD patients, regardless of their conventional cost-effectiveness compared to standard-of-care (SOC). The researchers emphasized the importance of considering patient-population-specific equity in decision-making and funding allocation. This study provides valuable insights into the potential benefits of gene therapy and allotransplantation for SCD patients. [Extracted from the article]

Researchers at New York University Langone Health have explored non-invasive and minimally invasive approaches to diagnosing and monitoring rejection in Vascularized Composite Allotransplantation (VCA). They reviewed literature and found promising modalities such as imaging, liquid biomarkers, epidermal sampling, clinical grading scales, and introducing additional donor tissue. Serum biomarkers and epidermal sampling showed potential for monitoring rejection, while clinical grading scales and reflection confocal microscopy were useful diagnostically. The researchers concluded that further research is needed and a multimodal algorithmic approach should be explored. This research has been peer-reviewed and published in Transplantation Reviews. [Extracted from the article]

A recent study conducted by researchers from University Hospital Regensburg in Germany explores the potential application of artificial intelligence (AI) in facial vascularized composite allotransplantation (FVCA), a field of reconstructive surgery for patients with severe facial disfigurements. The study highlights the promising outcomes of FVCA and the challenges in integrating these procedures into standard workflows. The researchers discuss the use of AI technology for FVCA outcome simulation, diagnosis and prediction of rejection episodes, and malignancy screening. This research lays the groundwork for future studies linking AI and FVCA, offering targeted and resource-effective solutions for clinical challenges in this field. [Extracted from the article]

Cells expressing CSF1R in grafts were identified as recipient-derived myeloid cells of Cx3cr1 lineage, and these cells rarely expressed smooth muscle marker proteins. Bronx, State:New York, United States, North and Central America, Allogeneic Transplant, Allograft, Allotransplantation, Biomedicine, Connective Tissue Cells, Health and Medicine, Homograft, Immunology, Macrophages, Mononuclear Phagocyte System, Myeloid Cells, Phagocytes, Surgery, Transplant Medicine Keywords: Bronx; State:New York; United States; North and Central America; Allogeneic Transplant; Allograft; Allotransplantation; Biomedicine; Connective Tissue Cells; Health and Medicine; Homograft; Immunology; Macrophages; Mononuclear Phagocyte System; Myeloid Cells; Phagocytes; Surgery; Transplant Medicine EN Bronx State:New York United States North and Central America Allogeneic Transplant Allograft Allotransplantation Biomedicine Connective Tissue Cells Health and Medicine Homograft Immunology Macrophages Mononuclear Phagocyte System Myeloid Cells Phagocytes Surgery Transplant Medicine 366 366 1 10/30/23 20231102 NES 231102 2023 NOV 2 (NewsRx) -- By a News Reporter-Staff News Editor at Blood Weekly -- New research on Transplant Medicine - Allotransplantation is the subject of a report. [Extracted from the article]

A patent application has been submitted for a method of genetically engineering non-human animal donors to produce transplantable cells, tissues, and organs that are compatible with humans. The researchers aim to address the shortage of organs available for transplant and the risks associated with transplantation. By modifying the genome of pigs, the researchers hope to create genetically engineered animals that can provide organs for transplantation without triggering rejection by the human immune system. The method involves silencing or modifying specific proteins or molecules in the donor animals to render their products compatible with humans. The patent application also includes methods for ensuring the absence of certain pathogens in the genetically modified animals. [Extracted from the article]

Cell- based therapies have emerged as an attractive strategy for tolerance induction in VCA. Allogeneic Transplant, Allograft, Allotransplantation, Biological Therapy, Biomedicine, Clinical Trials and Studies, Health and Medicine, Homograft, Immunology, Immunomodulation, Pre-Trial Research, Risk and Prevention, Stem Cell Research, Surgery, Transplant Medicine Keywords: Allogeneic Transplant; Allograft; Allotransplantation; Biological Therapy; Biomedicine; Clinical Trials and Studies; Health and Medicine; Homograft; Immunology; Immunomodulation; Pre-Trial Research; Risk and Prevention; Stem Cell Research; Surgery; Transplant Medicine EN Allogeneic Transplant Allograft Allotransplantation Biological Therapy Biomedicine Clinical Trials and Studies Health and Medicine Homograft Immunology Immunomodulation Pre-Trial Research Risk and Prevention Stem Cell Research Surgery Transplant Medicine 363 363 1 10/24/23 20231027 NES 231027 2023 OCT 26 (NewsRx) -- By a News Reporter-Staff News Editor at Stem Cell Week -- Research findings on allotransplantation are discussed in a new report. [Extracted from the article]

Keywords: Allogeneic Transplant; Allograft; Allotransplantation; Biomedicine; Genetics; Health and Medicine; Homograft; Immunology; Surgery; Transplant Medicine EN Allogeneic Transplant Allograft Allotransplantation Biomedicine Genetics Health and Medicine Homograft Immunology Surgery Transplant Medicine 226 226 1 10/16/23 20231019 NES 231019 2023 OCT 19 (NewsRx) -- By a News Reporter-Staff News Editor at Blood Weekly -- Data detailed on allotransplantation have been presented. Allogeneic Transplant, Allograft, Allotransplantation, Biomedicine, Genetics, Health and Medicine, Homograft, Immunology, Surgery, Transplant Medicine. [Extracted from the article]

Keywords: Allogeneic Transplant; Allograft; Allotransplantation; Biomedicine; Health and Medicine; Homograft; Surgery; Transplant Medicine EN Allogeneic Transplant Allograft Allotransplantation Biomedicine Health and Medicine Homograft Surgery Transplant Medicine 626 626 1 08/28/23 20230903 NES 230903 2023 AUG 31 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- Investigators publish new report on allotransplantation. Allogeneic Transplant, Allograft, Allotransplantation, Biomedicine, Health and Medicine, Homograft, Surgery, Transplant Medicine. [Extracted from the article]

Keywords: Allogeneic Transplant; Allograft; Allotransplantation; Biomedicine; Health and Medicine; Homograft; Surgery; Transplant Medicine EN Allogeneic Transplant Allograft Allotransplantation Biomedicine Health and Medicine Homograft Surgery Transplant Medicine 390 390 1 07/31/23 20230803 NES 230803 2023 AUG 3 (NewsRx) -- By a News Reporter-Staff News Editor at Blood Weekly -- A new study on allotransplantation is now available. Allogeneic Transplant, Allotransplantation, Allograft, Biomedicine, Health and Medicine, Surgery, Transplant Medicine, Homograft. [Extracted from the article]

Allogeneic Transplant, Allograft, Allotransplantation, Biomedicine, Health and Medicine, Homograft, Surgery, Transplant Medicine Keywords: Allogeneic Transplant; Allograft; Allotransplantation; Biomedicine; Health and Medicine; Homograft; Surgery; Transplant Medicine EN Allogeneic Transplant Allograft Allotransplantation Biomedicine Health and Medicine Homograft Surgery Transplant Medicine 466 466 1 07/03/23 20230706 NES 230706 2023 JUL 6 (NewsRx) -- By a News Reporter-Staff News Editor at Blood Weekly -- Current study results on allotransplantation have been published. [Extracted from the article]

Allogeneic Transplant, Allograft, Allotransplantation, Biomedicine, Health and Medicine, Homograft, Surgery, Transplant Medicine Keywords: Allogeneic Transplant; Allograft; Allotransplantation; Biomedicine; Health and Medicine; Homograft; Surgery; Transplant Medicine EN Allogeneic Transplant Allograft Allotransplantation Biomedicine Health and Medicine Homograft Surgery Transplant Medicine 263 263 1 06/12/23 20230615 NES 230615 2023 JUN 15 (NewsRx) -- By a News Reporter-Staff News Editor at Blood Weekly -- Investigators publish new report on allotransplantation. Keywords for this news article include: New York University (NYU), Biomedicine, Surgery, Allograft, Homograft, Allotransplantation, Health and Medicine, Transplant Medicine, Allogeneic Transplant. [Extracted from the article]

Allogeneic Transplant, Allograft, Allotransplantation, Biomedicine, Drugs and Therapies, Health and Medicine, Homograft, Immunology, Pharmaceuticals, Surgery, Transplant Medicine Keywords for this news article include: University Hospital Regensburg, Regensburg, Germany, Europe, Biomedicine, Pharmaceuticals, Surgery, Allograft, Homograft, Immunology, Allotransplantation, Drugs and Therapies, Health and Medicine, Transplant Medicine, Allogeneic Transplant. Keywords: Allogeneic Transplant; Allograft; Allotransplantation; Biomedicine; Drugs and Therapies; Health and Medicine; Homograft; Immunology; Pharmaceuticals; Surgery; Transplant Medicine EN Allogeneic Transplant Allograft Allotransplantation Biomedicine Drugs and Therapies Health and Medicine Homograft Immunology Pharmaceuticals Surgery Transplant Medicine 253 253 1 05/29/23 20230601 NES 230601 2023 JUN 1 (NewsRx) -- By a News Reporter-Staff News Editor at Blood Weekly -- Data detailed on allotransplantation have been presented. [Extracted from the article]

Allogeneic Transplant, Allograft, Allotransplantation, Biomedicine, Health and Medicine, Homograft, Legal Issues, Surgery, Technology, Transplant Medicine Keywords: Allogeneic Transplant; Allograft; Allotransplantation; Biomedicine; Health and Medicine; Homograft; Legal Issues; Surgery; Technology; Transplant Medicine EN Allogeneic Transplant Allograft Allotransplantation Biomedicine Health and Medicine Homograft Legal Issues Surgery Technology Transplant Medicine 77 77 1 04/03/23 20230404 NES 230404 2023 APR 6 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- Current study results on allotransplantation have been published. Keywords for this news article include: Burn Trauma Center, Ludwigshafen, Germany, Europe, Biomedicine, Surgery, Allograft, Homograft, Technology, Legal Issues, Allotransplantation, Health and Medicine, Transplant Medicine, Allogeneic Transplant. [Extracted from the article]

Allogeneic Transplant, Allograft, Allotransplantation, Asia, Biomedicine, Health and Medicine, Homograft, Surgery, Transplant Medicine Keywords: Allogeneic Transplant; Allograft; Allotransplantation; Asia; Biomedicine; Health and Medicine; Homograft; Surgery; Transplant Medicine EN Allogeneic Transplant Allograft Allotransplantation Asia Biomedicine Health and Medicine Homograft Surgery Transplant Medicine 440 440 1 04/03/23 20230404 NES 230404 2023 APR 6 (NewsRx) -- By a News Reporter-Staff News Editor at Medical Devices & Surgical Technology Week -- Researchers detail new data in allotransplantation. Keywords for this news article include: Yonsei University College of Medicine, Asia, Biomedicine, Surgery, Allograft, Homograft, Allotransplantation, Health and Medicine, Transplant Medicine, Allogeneic Transplant. [Extracted from the article]

Allogeneic Transplant, Allograft, Allotransplantation, Biomedicine, Health and Medicine, Homograft, Surgery, Transplant Medicine Keywords for this news article include: Center for Medical Device Evaluation, Biomedicine, Surgery, Allograft, Homograft, Allotransplantation, Health and Medicine, Transplant Medicine, Allogeneic Transplant. Keywords: Allogeneic Transplant; Allograft; Allotransplantation; Biomedicine; Health and Medicine; Homograft; Surgery; Transplant Medicine EN Allogeneic Transplant Allograft Allotransplantation Biomedicine Health and Medicine Homograft Surgery Transplant Medicine 2023 MAR 9 (NewsRx) -- By a News Reporter-Staff News Editor at Blood Weekly -- Investigators publish new report on allotransplantation. [Extracted from the article]

For more information on this research see: Implantable Niche With Local Immunosuppression for Islet Allotransplantation Achieves Type 1 Diabetes Reversal In Rats. Keywords: Houston; State:Texas; United States; North and Central America; Allogeneic Transplant; Allograft; Allotransplantation; Biomedicine; Health and Medicine; Homograft; Immunology; Immunosuppression; Insulin Dependent Diabetes Mellitus; Nutritional and Metabolic Diseases and Conditions; Surgery; Transplant Medicine; Type 1 Diabetes EN Houston State:Texas United States North and Central America Allogeneic Transplant Allograft Allotransplantation Biomedicine Health and Medicine Homograft Immunology Immunosuppression Insulin Dependent Diabetes Mellitus Nutritional and Metabolic Diseases and Conditions Surgery Transplant Medicine Type 1 Diabetes 2023 FEB 16 (NewsRx) -- By a News Reporter-Staff News Editor at Diabetes Week -- A new study on Nutritional and Metabolic Diseases and Conditions - Type 1 Diabetes is now available. [Extracted from the article]

Keywords: Toronto; Canada; North and Central America; Allogeneic Transplant; Allograft; Allotransplantation; Bioengineering; Biomedical Engineering; Biomedicine; Biotechnology; Health and Medicine; Homograft; Surgery; Tissue Engineering; Transplant Medicine EN Toronto Canada North and Central America Allogeneic Transplant Allograft Allotransplantation Bioengineering Biomedical Engineering Biomedicine Biotechnology Health and Medicine Homograft Surgery Tissue Engineering Transplant Medicine 2023 FEB 9 (NewsRx) -- By a News Reporter-Staff News Editor at Blood Weekly -- Current study results on Biomedical Engineering - Tissue Engineering have been published. Keywords for this news article include: Toronto, Canada, North and Central America, Allogeneic Transplant, Allograft, Allotransplantation, Bioengineering, Biomedical Engineering, Biomedicine, Biotechnology, Health and Medicine, Homograft, Surgery, Tissue Engineering, Transplant Medicine, University Health Network. [Extracted from the article]